About PharmGKB

The PharmGKB is a pharmacogenomics knowledge resource that encompasses clinical information including dosing guidelines and drug labels, potentially clinically actionable gene-drug associations and genotype-phenotype relationships. PharmGKB collects, curates and disseminates knowledge about the impact of human genetic variation on drug responses through the following activities:

  • Annotate genetic variants and gene-drug-disease relationships via literature reviews
  • Summarize important pharmacogenomic genes, associations between genetic variants and drugs, and drug pathways
  • Curate FDA , EMA, PMDA, and HCSC drug labels containing pharmacogenomic information
  • Enable consortia examining important questions in pharmacogenomics
  • Curate and participate in writing pharmacogenomic-based drug dosing guidelines
  • Contribute to clinical implementation projects for pharmacogenomics through collaborations
  • Publish pharmacogenomic-based drug dosing guidelines, very important pharmacogene summaries and drug-centered pathways
  • Display all information on the website and provide comprehensive downloads

Contact

Teri E. Klein, PhD

CoPI & Director, PharmGKB

CoPI, CPIC

teri.klein@stanford.edu


Russ B. Altman, MD PhD

The Kenneth Fong Professor of Engineering

Professor, Bioengineering, Genetics, & Medicine

CoPI PharmGKB

russ.altman@stanford.edu

Tiffany Murray

Genetics & Medicine

Shriram Center

tiffany.murray@stanford.edu

Type of Award: R24

Grant Number: 1 R24 GM061374-16

Copyright © 2020 the Pharmacogenomics Research Network. All Rights Reserved.

Become a member

PGRN logo
Membership dues are vital to continue the mission and work of the PGRN. Founding Members will be listed on the PGRN website. 
Powered by Wild Apricot Membership Software